Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
ZD 9379 br Acknowledgments This work was funded
2020-03-10

Acknowledgments This work was funded by the EU ERDF and the Spanish Ministry of Economy and Competitiveness (MINECO) under Project TIN2013-41576-R, and the Spanish Ministry of Education, Culture and Sport (MECD) under a FPU grant (AP2010-3259), and the Andalusian Regional Government (Spain) under
-
UVRAG is a mammalian ortholog of yeast Vps
2020-03-10

UVRAG is a mammalian ortholog of yeast Vps38 and a promoter of autophagy [51,60,61]. It forms distinct complexes with BECN1 (mammalian ortholog of yeast Vps30/Atg6) and the class III phosphatidylinositol 3-kinase (whose catalytic subunit [PIK3C3] is the mammalian ortholog of yeast Vps34) and contrib
-
EphB appears to be a low affinity receptor
2020-03-10

EphB4 appears to be a low-affinity receptor for rhEpo based on the biochemical data. The concentration of rhEpo used for the biological experiments (50 IU/ml) corresponds to 10–15 nM, which is 1% to 2% of the KD value (KD = 881 nM) for the binding of rhEpo to EphB4, as measured in the MST assay. The
-
Based upon these findings on portions A and
2020-03-10

Based upon these findings on portions A and B, novel scaffolds of EP4 antagonist, and (R & R=()-Me; =Cl; R=H), shown in , were identified. We next focused on optimizing portion C of these scaffolds. We utilized for an alternative synthesis of nicotinamide scaffold , which is quite effective for
-
From these and other studies
2020-03-10

From these and other studies, it is clear that acriflavine is an interesting Zinc protoporphyrin IX with pleiotropic anticancer effects [21], [22], [43]. Its past systemic use in the clinical setting as an antibiotic without any major toxicity reported encourages further development of the drug for
-
DPP is show two relevant
2020-03-10

DPP-4is show two relevant benefits in the clinical management of type 2 diabetic patients: negligible risk of severe hypoglycemia, particularly when compared with sulphonylureas [[33], [34]], and weight neutrality, in contrast with the weight gain generally observed with insulin therapy, sulfonylure
-
br Conclusion br Conflict of interest br Acknowledgment The
2020-03-10

Conclusion Conflict of interest Acknowledgment The authors acknowledge the grant support of the Tehran University of Medical Sciences (94-02-49-29647). Introduction Earlier in vitro observations have also established that the human 5-HT2A, while very similar to the rat isoform, exhibits
-
However there are still some issues that remain
2020-03-10

However, there are still some issues that remain poorly understood. For instance, how TGF-β modulates DDR2 expression and whether Smads participate in the regulation. How does DDR2 regulate the expression of PTHrP via Runx2? Is there any other kinase downstream of DDR2 participating in PTHrP regulat
-
Electroencephalographs at onset ranged from hypsarrhythmia
2020-03-10

Electroencephalographs at onset ranged from hypsarrhythmia to mild abnormalities but more abnormalities in background rhythms and epileptiform activity develop over time.15, 17, 19, 48, 52, 54, 55 Early mild abnormalities that sometimes precede a diffuse encephalopathy included focal delta slowing i
-
This study demonstrates that GUL
2020-03-10

This study demonstrates that GUL-1 affects multiple pathways/processes. As GUL-1 is likely to function as an RNA-binding protein, it is conceivable that the mRNAs involved are bound to GUL-1 as part of the regulatory function of the protein. In fact, in S. cerevisiae Ssd1 was shown to bind multiple
-
This article is based on previous
2020-03-10

This article is based on previous research work [43] in the field of distributed development of information systems [34]. In that work, the system infrastructure focusing on the three-level data model used in the different layers of our architecture is described. The work presented in this manuscrip
-
96 7 sale br Conclusion In this review we
2020-03-10

Conclusion In this review, we have discussed how inhibition of the CK2/CDK5 signaling axis protects WM only when inhibited before ischemia, while inhibition of the CK2/AKT/GSK3β signaling axis protects WM either before or after an ischemic injury in young, aging, and old WM (Fig. 3). CK2 activati
-
NPC L NPC Niemann Pick C like like intracellular
2020-03-09

NPC1L1 (NPC1 [Niemann-Pick C-like-1]-like intracellular cholesterol transporter) is the rate-limiting transmembrane transporter for cholesterol happen to you from the intestinal lumen, and it mediates the absorption of both dietary and biliary cholesterol., , NPC1L1 is the target of the cholestero
-
br Introduction Breast cancer is the most common malignant t
2020-03-09

Introduction Breast cancer is the most common malignant tumor in women and the second leading cause of female death [1]. In recent years, with the improvement of early detection and the emergence of new treatment methods, the mortality rate of breast cancer has been greatly reduced. However, the
-
ELUXA HM EMSI is an ongoing pivotal Phase II
2020-03-09

ELUXA 1 (HM-EMSI-202) is an ongoing pivotal Phase II global clinical trial, designed to further investigate the efficacy and safety of Olmutinib in patients T790M-positive NSCLC with acquired resistance after first-line EGFR TKIs. Primary endpoint is ORR according to RECIST 1.1, while secondary endp
16098 records 892/1074 page Previous Next First page 上5页 891892893894895 下5页 Last page